Cytostatic anticancer drugs are known as carcinogenic, mutagenic, and teratogenic risk factors for health care workers occupationally exposed. It has been demonstrated that the administration of interleukin-15 in rat models of colon carcinoma protects against chemotherapy-induced gastrointestinal toxicities. We found that occupational exposure to chemotherapeutic antiblastic agents in vivo modified circulating levels of interleukin-15 in 17 health care workers exposed to antineoplastic drugs in relation to their jobs and in as many healthy age- and sex-matched subjects. Health care workers displayed significantly higher circulating interleukin-15 levels compared to their age-matched controls. If this increase representing an anticancer response remains to be established, these findings strengthen the idea of a therapeutic use of interleukin-15 in the field of cancer. © 2005 Hindawi Publishing Corporation.
Spatari G., Fenga C., Minciullo P.L., Di Pasquale G., Cacciola A., Ventura-Spagnolo E., et al. (2005). Modification of interleukin-15 serum levels in workers exposed to chemotherapeutic agents. MEDIATORS OF INFLAMMATION, 2005(1), 60-62 [10.1155/MI.2005.60].
Modification of interleukin-15 serum levels in workers exposed to chemotherapeutic agents
Ventura-Spagnolo E.Membro del Collaboration Group
;
2005-01-01
Abstract
Cytostatic anticancer drugs are known as carcinogenic, mutagenic, and teratogenic risk factors for health care workers occupationally exposed. It has been demonstrated that the administration of interleukin-15 in rat models of colon carcinoma protects against chemotherapy-induced gastrointestinal toxicities. We found that occupational exposure to chemotherapeutic antiblastic agents in vivo modified circulating levels of interleukin-15 in 17 health care workers exposed to antineoplastic drugs in relation to their jobs and in as many healthy age- and sex-matched subjects. Health care workers displayed significantly higher circulating interleukin-15 levels compared to their age-matched controls. If this increase representing an anticancer response remains to be established, these findings strengthen the idea of a therapeutic use of interleukin-15 in the field of cancer. © 2005 Hindawi Publishing Corporation.
| File | Dimensione | Formato | |
|---|---|---|---|
|
Modification of interleukin 15_2005.pdf
accesso aperto
Descrizione: articolo principale
Tipologia:
Post-print
Dimensione
47.33 kB
Formato
Adobe PDF
|
47.33 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
